이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Joinn Laboratories(China)Co.Ltd 관리

관리 기준 확인 3/4

Joinn Laboratories(China)Co.Ltd's CEO는 Dapeng Gao, Mar2013 에 임명되었습니다 의 임기는 11.25 년입니다. 는 CN¥ 4.18M 가치에 해당하는 회사 주식의 0.043% 직접 소유합니다. 4.18M. 경영진과 이사회의 평균 재임 기간은 각각 11.5 년과 5.4 년입니다.

주요 정보

Dapeng Gao

최고 경영자

CN¥1.9m

총 보상

CEO 급여 비율	n/a
CEO 임기	11.3yrs
CEO 소유권	0.04%
경영진 평균 재임 기간	11.6yrs
이사회 평균 재임 기간	5.5yrs

최근 관리 업데이트

Recent updates

Joinn Laboratories(China)Co.,Ltd. (SHSE:603127) Analysts Just Cut Their EPS Forecasts Substantially

Apr 08

There May Be Reason For Hope In Joinn Laboratories(China)Co.Ltd's (SHSE:603127) Disappointing Earnings

Apr 04

CEO 보상 분석

Dapeng Gao 의 보수는 Joinn Laboratories(China)Co.Ltd 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Mar 31 2024	n/a	n/a	-CN¥63m
Dec 31 2023	CN¥2m	n/a	CN¥397m
Sep 30 2023	n/a	n/a	CN¥770m
Jun 30 2023	n/a	n/a	CN¥794m
Mar 31 2023	n/a	n/a	CN¥1b
Dec 31 2022	CN¥2m	n/a	CN¥1b
Sep 30 2022	n/a	n/a	CN¥941m
Jun 30 2022	n/a	n/a	CN¥775m
Mar 31 2022	n/a	n/a	CN¥589m
Dec 31 2021	CN¥2m	CN¥644k	CN¥557m
Sep 30 2021	n/a	n/a	CN¥419m
Jun 30 2021	n/a	n/a	CN¥379m
Mar 31 2021	n/a	n/a	CN¥389m
Dec 31 2020	CN¥2m	CN¥573k	CN¥315m
Sep 30 2020	n/a	n/a	CN¥253m
Jun 30 2020	n/a	n/a	CN¥237m
Mar 31 2020	n/a	n/a	CN¥194m
Dec 31 2019	CN¥1m	CN¥483k	CN¥187m

보상 대 시장: Dapeng 의 총 보상 ($USD 261.89K )은 CN 시장( $USD 175.25K ).

보상과 수익: Dapeng 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Dapeng Gao (42 yo)

11.3yrs

테뉴어

CN¥1,901,300

보상

Mr. Dapeng Gao is the Executive Director of Joinn Laboratories (China) Co.,Ltd. since August 2020 and has been its General Manager since January 28, 2019 and Joint Secretary since January 2019 and August 2...

리더십 팀

이름	위치	테뉴어	보상	소유권
Yuxia Feng	Founder & Chairman	11.6yrs	CN¥3.21m	22.38% CN¥ 2.1b
Dapeng Gao	GM, Secretary to the Board	11.3yrs	CN¥1.90m	0.043% CN¥ 3.9m
Conglin Zuo	Co-Founder & Vice Chairman	11.6yrs	CN¥1.90m	1.89% CN¥ 174.0m
Aishui Yu	Chief Financial Officer	5yrs	CN¥1.26m	0.0046% CN¥ 421.4k
Jingliang Gu	Vice GM & Head of Sales Department	13.5yrs	CN¥1.86m	0.036% CN¥ 3.3m
Yunxia Sun	Vice GM & Executive Director	11.6yrs	CN¥1.86m	0.36% CN¥ 33.3m
Dalin Yao	Senior Vice GM	12.4yrs	CN¥1.86m	0.010% CN¥ 944.2k

11.6yrs

평균 재임 기간

56yo

평균 연령

경험이 풍부한 관리: 603127 의 관리팀은 노련하고 경험 (평균 재직 기간 11.5 년)입니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Yuxia Feng	Founder & Chairman	11.6yrs	CN¥3.21m	22.38% CN¥ 2.1b
Dapeng Gao	GM, Secretary to the Board	10.8yrs	CN¥1.90m	0.043% CN¥ 3.9m
Conglin Zuo	Co-Founder & Vice Chairman	11.6yrs	CN¥1.90m	1.89% CN¥ 174.0m
Yunxia Sun	Vice GM & Executive Director	5.5yrs	CN¥1.86m	0.36% CN¥ 33.3m
Dalin Yao	Senior Vice GM	5.5yrs	CN¥1.86m	0.010% CN¥ 944.2k
Ye Li	Supervisor	11.6yrs	데이터 없음	0.014% CN¥ 1.3m
Mingcheng Sun	Independent Non-Executive Director	5.5yrs	CN¥150.00k	데이터 없음
Yonggong Zhai	Independent Non-Executive Director	5.5yrs	CN¥150.00k	데이터 없음
Xiaojie Ou	Independent Non-Executive Director	5.5yrs	CN¥150.00k	데이터 없음
Fan Zhang	Independent Non-Executive Director	3.4yrs	CN¥162.00k	데이터 없음
Yingjun He	Chairman of the Supervisory Board	1.7yrs	데이터 없음	데이터 없음

5.5yrs

평균 재임 기간

51yo

평균 연령

경험이 풍부한 이사회: 603127 의 이사회는 경험(평균 재직 기간 5.4 년)으로 간주됩니다.

Joinn Laboratories(China)Co.Ltd 관리

관리 기준 확인 3/4

주요 정보

최근 관리 업데이트

Joinn Laboratories(China)Co.,Ltd., Annual General Meeting, Jun 20, 2024

GM, Secretary to the Board recently sold CN¥2.5m worth of stock

Co-Founder & Vice Chairman recently sold CN¥6.2m worth of stock

Vice GM & Executive Director recently sold CN¥6.9m worth of stock

Co-Founder & Vice Chairman recently sold CN¥12m worth of stock

Co-Founder & Vice Chairman recently sold CN¥12m worth of stock

Recent updates

Joinn Laboratories(China)Co.,Ltd. to Report First Half, 2024 Results on Aug 31, 2024

Joinn Laboratories(China)Co.,Ltd., Annual General Meeting, Jun 20, 2024

New minor risk - Share price stability

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Joinn Laboratories(China)Co.,Ltd. (SHSE:603127) Analysts Just Cut Their EPS Forecasts Substantially

There May Be Reason For Hope In Joinn Laboratories(China)Co.Ltd's (SHSE:603127) Disappointing Earnings

Consensus revenue estimates fall by 19%

Joinn Laboratories(China)Co.,Ltd. to Report Q1, 2024 Results on Apr 30, 2024

Consensus EPS estimates fall by 19%

Price target decreased by 8.6% to CN¥22.33

Investor sentiment improves as stock rises 19%

Now 23% undervalued after recent price drop

Investor sentiment deteriorates as stock falls 19%

Now 23% undervalued after recent price drop

Now 23% undervalued after recent price drop

Joinn Laboratories(China)Co.,Ltd. Provides Earnings Guidance for the Year Ended December 31, 2023

Price target decreased by 7.2% to CN¥25.92

Price target decreased by 7.3% to CN¥28.66

Now 20% undervalued after recent price drop

Joinn Laboratories(China)Co.,Ltd. to Report Fiscal Year 2023 Results on Mar 29, 2024

GM, Secretary to the Board recently sold CN¥2.5m worth of stock

Consensus EPS estimates fall by 27%

Now 20% undervalued after recent price drop

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Consensus EPS estimates increase by 700%

New minor risk - Share price stability

Co-Founder & Vice Chairman recently sold CN¥6.2m worth of stock

Vice GM & Executive Director recently sold CN¥6.9m worth of stock

Consensus EPS estimates increase by 24%

Consensus EPS estimates fall by 10%

Price target decreased by 11% to CN¥33.30

Second quarter 2023 earnings: EPS exceeds analyst expectations

Price target decreased by 13% to CN¥37.55

Now 25% undervalued after recent price drop

Joinn Laboratories(China)Co.,Ltd. Provides Earnings Guidance for the Six Months Ended 30 June 2023

Price target decreased by 8.7% to CN¥57.93

Co-Founder & Vice Chairman recently sold CN¥12m worth of stock

Co-Founder & Vice Chairman recently sold CN¥12m worth of stock

Co-Founder & Vice Chairman recently sold CN¥8.9m worth of stock

Joinn Laboratories (China) Co.,Ltd. Declares Final Dividend for the Year Ended December 31, 2022, Payable on 20 July 2023

Joinn Laboratories(China)Co.,Ltd., Annual General Meeting, Jun 09, 2023

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased by 7.4% to CN¥70.19

Price target increased by 7.4% to CN¥76.57

Insider recently sold CN¥56m worth of stock

JOINN Laboratories (China) Co., Ltd. Provides Revenue Guidance for the Period January 1, 2022 to December 31, 2022

Insider recently sold CN¥57m worth of stock

Co-Founder & Vice Chairman recently sold CN¥31m worth of stock

Insider recently sold CN¥30m worth of stock

Co-Founder & Vice Chairman recently sold CN¥65m worth of stock

Price target decreased to CN¥71.30

Less than half of directors are independent

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Now 21% undervalued after recent price drop

Co-Founder & Vice Chairman recently sold CN¥180m worth of stock

Price target increased to CN¥86.02

Insider recently sold CN¥60m worth of stock

Now 21% undervalued after recent price drop

Price target decreased to CN¥74.80

Second quarter 2022 earnings released: EPS: CN¥0.46 (vs CN¥0.11 in 2Q 2021)

Joinn Laboratories(China)Co.,Ltd. SHS (China) to Be Deleted from OTC Equity

Joinn Laboratories(China)Co.,Ltd. to Report Q2, 2022 Results on Aug 30, 2022

Joinn Laboratories(China)Co.,Ltd. Provides Earnings Guidance for the Period from 1 January 2022 to 30 June 2022

Senior Vice GM recently sold CN¥233k worth of stock

Joinn Laboratories(China)Co.,Ltd. Approves Final Dividend in Cash for the Year Ended December 31, 2021, Payable on 23 August 2022

Vice GM & Executive Director recently sold CN¥4.6m worth of stock

Founder & Chairman recently sold CN¥51m worth of stock

Investor sentiment improved over the past week

Joinn Laboratories (China) Co.,Ltd. Proposes Final Cash Dividend for the Year Ended December 31, 2021, Payable on 23 August 2022